177944-77-3 Usage
Uses
Used in Pharmaceutical Industry:
2,3-Quinoxalinedione,1,4-dihydro-,monooxime(9CI) is used as a potential intermediate in organic synthesis for the development of pharmaceutical compounds. Its unique structure may contribute to the creation of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 2,3-Quinoxalinedione,1,4-dihydro-,monooxime(9CI) may be utilized as a precursor for the synthesis of agrochemicals, such as pesticides or herbicides, due to its heterocyclic nature and potential reactivity in chemical reactions.
Used in Materials Science:
2,3-Quinoxalinedione,1,4-dihydro-,monooxime(9CI) could be explored for use in materials science, potentially contributing to the development of new materials with unique properties, such as conductivity, stability, or reactivity, based on its heterocyclic structure and chemical composition.
Check Digit Verification of cas no
The CAS Registry Mumber 177944-77-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,7,9,4 and 4 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 177944-77:
(8*1)+(7*7)+(6*7)+(5*9)+(4*4)+(3*4)+(2*7)+(1*7)=193
193 % 10 = 3
So 177944-77-3 is a valid CAS Registry Number.
177944-77-3Relevant academic research and scientific papers
Glycine receptor antagonist pharmacophore
-
, (2008/06/13)
Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer''s disease, amyotrophic lateral sclerosis, Huntington''s disease and Down''s syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions and inducing anesthesia are disclosed by administering to an animal in need of such treatment a compound which has high binding to the glycine receptor.
